General Information

Artifact Type
Poster
Title: Computational Modeling of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)
Abstract/Short Description

CAR T-cell therapy has impressive anti-tumor activity in a variety of hematologic cancers including pediatric acute lymphoblastic leukemia (ALL), diffuse large B-cell non-Hodgkin’s lymphoma (NHL), mantle cell NHL, multiple myeloma, and chronic lymphocytic leukemia (CLL), leading to the commercial approval of four CD19-directed CAR T-cell products. While CAR T-cells are promising treatments for relapsed/refractory hematologic cancers, they are limited by two significant toxicities, CRS and ICANS. Proven management options for CRS and ICANS are limited to tocilizumab and corticosteroids.

Files
Attachment Size
Aubrey.Winter_ICANS.pdf 4.96 MB

Authorship

Authors
Winger A
Klahn B
Warren A
Hoops S
Marathe M
Lee D
Kindwall-Keller T

Publication Details

Year
2022
Month
April
Day
26
Publication/Conference Proceeding Name
Biocomplexity Institute Spring 2022 Research Symposium
Publisher/Conference Name
UVA Biocomplexity Institute and Initiative
There is no available external link for this item
Off

Other Information

Division
Network Systems Science and Advanced Computing
Institute Technical Report Number
BI-2022-1684